KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBITDA Margin (2016 - 2025)

Acadia Pharmaceuticals has reported EBITDA Margin over the past 16 years, most recently at 6.12% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 5301.0% year-over-year to 6.12%; the TTM value through Dec 2025 reached 9.78%, down 1431.0%, while the annual FY2025 figure was 9.78%, 1431.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 6.12% at Acadia Pharmaceuticals, down from 12.83% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 97.23% in Q4 2022 and troughed at 97.88% in Q1 2022.
  • A 5-year average of 6.02% and a median of 3.98% in 2023 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: plummeted -16672bps in 2021 and later soared 13138bps in 2022.
  • Year by year, EBITDA Margin stood at 34.15% in 2021, then soared by 385bps to 97.23% in 2022, then plummeted by -84bps to 15.12% in 2023, then surged by 291bps to 59.13% in 2024, then crashed by -90bps to 6.12% in 2025.
  • Business Quant data shows EBITDA Margin for ACAD at 6.12% in Q4 2025, 12.83% in Q3 2025, and 12.24% in Q2 2025.